227
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prediction of the P. falciparum Target Space Relevant to Malaria Drug Discovery

      research-article
      , *
      PLoS Computational Biology
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Malaria is still one of the most devastating infectious diseases, affecting hundreds of millions of patients worldwide. Even though there are several established drugs in clinical use for malaria treatment, there is an urgent need for new drugs acting through novel mechanisms of action due to the rapid development of resistance. Resistance emerges when the parasite manages to mutate the sequence of the drug targets to the extent that the protein can still perform its function in the parasite but can no longer be inhibited by the drug, which then becomes almost ineffective. The design of a new generation of malaria drugs targeting multiple essential proteins would make it more difficult for the parasite to develop full resistance without lethally disrupting some of its vital functions. The challenge is then to identify which set of Plasmodium falciparum proteins, among the millions of possible combinations, can be targeted at the same time by a given chemotype. To do that, we predicted first the targets of the close to 20,000 antimalarial hits identified recently in three independent phenotypic screening campaigns. All targets predicted were then projected onto the genome of P. falciparum using orthologous relationships. A total of 226 P. falciparum proteins were predicted to be hit by at least one compound, of which 39 were found to be significantly enriched by the presence and degree of affinity of phenotypically active compounds. The analysis of the chemically compatible target combinations containing at least one of those 39 targets led to the identification of a priority set of 64 multi-target profiles that can set the ground for a new generation of more robust malaria drugs.

          Author Summary

          There is an urgent need for new antimalarials acting through novel mechanisms of action that can overcome the increasing incidence of resistance observed for currently used drugs. In this respect, drug polypharmacology is emerging as an attractive strategy to reduce the chances of the parasite evolving drug resistance. Although there were close to 20,000 antimalarial hits recently identified from three independent phenotypic screenings, the molecular targets through which most of those active compounds exert their antimalarial action are unfortunately unknown at present. To address this issue, a computational approach was first used to predict their protein targets. Statistical analyses were applied to detect any enrichment of phenotypically active compounds in P. falciparum targets, leading to a final list of 39 putative high-priority targets for malaria drug discovery. The presence of at least one high-priority target in the target profile predicted for the antimalarial hits was then used as a constraint to identify a priority set of 64 multi-target profiles. Multi-target strategies based on such profiles can set the basis for designing a next generation of more robust malaria drugs.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Spiroindolones, a potent compound class for the treatment of malaria.

          Recent reports of increased tolerance to artemisinin derivatives--the most recently adopted class of antimalarials--have prompted a need for new treatments. The spirotetrahydro-beta-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chemical genetics of Plasmodium falciparum

            Malaria caused by Plasmodium falciparum is a catastrophic disease worldwide (880,000 deaths yearly). Vaccine development has proved difficult and resistance has emerged for most antimalarials. In order to discover new antimalarial chemotypes, we have employed a phenotypic forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire library, many of which exhibited potent in vitro activity against drug resistant strains, and detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. Phylochemogenetic profiling in multiple organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar compound displayed efficacy in a murine model. Overall, our findings provide the scientific community with new starting points for malaria drug discovery.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Molecular Mechanism of Action of Artemisinin—The Debate Continues

              Despite international efforts to ‘roll back malaria’ the 2008 World Malaria Report revealed the disease still affects approximately 3 billion people in 109 countries; 45 within the WHO African region. The latest report however does provide some ‘cautious optimism’; more than one third of malarious countries have documented greater than 50% reductions in malaria cases in 2008 compared to 2000. The goal of the Member States at the World Health Assembly and ‘Roll Back Malaria’ (RBM) partnership is to reduce the numbers of malaria cases and deaths recorded in 2000 by 50% or more by the end of 2010. Although malaria is preventable it is most prevalent in poorer countries where prevention is difficult and prophylaxis is generally not an option. The burden of disease has increased by the emergence of multi drug resistant (MDR) parasites which threatens the use of established and cost effective antimalarial agents. After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitaemia and quick resolution of symptoms. Since artemisinin and its derivatives are eliminated rapidly, artemisinin combination therapies (ACT’s) are now recommended to delay resistance mechanisms. In spite of these precautionary measures reduced susceptibility of parasites to the artemisinin-based component of ACT’s has developed at the Thai-Cambodian border, a historical ‘hot spot’ for MDR parasite evolution and emergence. This development raises serious concerns for the future of the artemsinins and this is not helped by controversy related to the mode of action. Although a number of potential targets have been proposed the actual mechanism of action remains ambiguous. Interestingly, artemisinins have also shown potent and broad anticancer properties in cell lines and animal models and are becoming established as anti-schistosomal agents. In this review we will discuss the recent evidence explaining bioactivation and potential molecular targets in the chemotherapy of malaria and cancer.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Comput Biol
                PLoS Comput. Biol
                plos
                ploscomp
                PLoS Computational Biology
                Public Library of Science (San Francisco, USA )
                1553-734X
                1553-7358
                October 2013
                October 2013
                17 October 2013
                : 9
                : 10
                : e1003257
                Affiliations
                [1]Chemotargets SL and Systems Pharmacology, Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Parc de Recerca Biomèdica, Barcelona, Catalonia, Spain
                University of Heidelberg, Germany
                Author notes

                The authors have declared that no competing interests exist.

                Conceived and designed the experiments: AS JM. Performed the experiments: AS. Analyzed the data: AS JM. Contributed reagents/materials/analysis tools: AS JM. Wrote the paper: AS JM.

                Article
                PCOMPBIOL-D-13-00764
                10.1371/journal.pcbi.1003257
                3798273
                24146604
                3d012687-88eb-476e-96c0-8a160a458252
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 2 May 2013
                : 20 August 2013
                Page count
                Pages: 14
                Funding
                This work was supported by the Medicines for Malaria Venture (project no. MMV 12/0069), the Spanish Instituto de Salud Carlos III (Drugs4Rare project within the framework of the International Rare Disease Research Consortium), and the Spanish Ministerio de Ciencia e Innovación (project BIO2011-26669). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article

                Quantitative & Systems biology
                Quantitative & Systems biology

                Comments

                Comment on this article